Rare Disease Phase 3 Deal Benchmarks — US Only

Understanding Rare Disease Deal Benchmarks at Phase 3

Phase 3 Rare Disease licensing deals in US Only territory command a median upfront payment of $907M, with values ranging from $546M at the low end to $1.4B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.2B to $4.1B, with a median of $3.1B. Royalty rates for rare disease assets at this stage typically fall between 9% and 16.1% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.